A novel structural derivative of natural alkaloid ellipticine, MDPSQ, induces necrosis in leukemic cells M. S. ShahabuddinMridula NambiarSathees C. Raghavan PRECLINICAL STUDIES 13 January 2010 Pages: 523 - 533
Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo Hiroshi HiraiIkuko Takahashi-SuzikiYoshikazu Iwasawa PRECLINICAL STUDIES 19 January 2010 Pages: 534 - 543
Effects of the microtubule stabilizing agent peloruside A on the proteome of HL-60 cells Anja WilmesPisana RawsonJohn H. Miller PRECLINICAL STUDIES 27 January 2010 Pages: 544 - 553
AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo Mylin A. TorresUma RajuK. Kian Ang PRECLINICAL STUDIES 02 February 2010 Pages: 554 - 561
Cribrostatin 6 induces death in cancer cells through a reactive oxygen species (ROS)-mediated mechanism Mirth T. HoytRahul PalchaudhuriPaul J. Hergenrother PRECLINICAL STUDIES 20 February 2010 Pages: 562 - 573
LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin Jian-Jun GaoZu-Hua GaoXian-Jun Qu PRECLINICAL STUDIES 29 January 2010 Pages: 574 - 582
A natural compound, methyl angolensate, induces mitochondrial pathway of apoptosis in Daudi cells Kishore K. ChiruvellaSathees C. Raghavan PRECLINICAL STUDIES 20 February 2010 Pages: 583 - 592
The anti-proliferative side effects of AEE788, a tyrosine kinase inhibitor blocking both EGF- and VEGF-receptor, are liver-size-dependent after partial hepatectomy in rats Meihong DengHai HuangUta Dahmen PRECLINICAL STUDIES 12 February 2010 Pages: 593 - 606
Anticancer activity and mode of action of titanocene C Ulrike OlszewskiJames ClaffeyGerhard Hamilton PRECLINICAL STUDIES 17 February 2010 Pages: 607 - 614
Peloruside A inhibits microtubule dynamics in a breast cancer cell line MCF7 Ariane ChanPeter M. AndreaeJohn H. Miller PRECLINICAL STUDIES 20 February 2010 Pages: 615 - 626
Thioredxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest Jia-ning FuJing LiHui-hui Zeng PRECLINICAL STUDIES 02 March 2010 Pages: 627 - 636
Baicalin induces human mucoepidermoid carcinoma Mc3 cells apoptosis in vitro and in vivo Xiao-Fang XuBo-Lei CaiBin Liu PRECLINICAL STUDIES 06 March 2010 Pages: 637 - 645
B1, a novel naphthalimide-based DNA intercalator, induces cell cycle arrest and apoptosis in HeLa cells via p53 activation Xin LiangAibin WuXuhong Qian PRECLINICAL STUDIES 24 February 2010 Pages: 646 - 658
Suppressive effects of liquid crystal compounds on the growth of the A549 human lung cancer cell line Yuuka TakahashiMasaharu HazawaIkuo Kashiwakura PRECLINICAL STUDIES 17 March 2010 Pages: 659 - 665
Anoikis induction and metastasis suppression by a new integrin αvβ3 inhibitor in human melanoma cell line M21 Yongci ZhangMing YangYuan Zhou PRECLINICAL STUDIES 18 December 2010 Pages: 666 - 673
A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer Franklin M. ChuJoel PicusBrenda Foster PHASE I STUDIES 11 February 2010 Pages: 674 - 679
Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study Cheryl HoRandeep SanghaAngela M. Davies PHASE I STUDIES 12 February 2010 Pages: 680 - 687
Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS Kohei ShitaraTomoya YokotaKei Muro PHASE II STUDIES 14 January 2010 Pages: 688 - 693
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer Bassel Fuad El-RayesPhilip A. PhilipJames L. Abbruzzese PHASE II STUDIES 27 January 2010 Pages: 694 - 699
Factual understanding of randomized clinical trials: a multicenter case-control study in cancer patients Tanguy LeroyVéronique ChristopheStéphanie Clisant PHASE III STUDIES 18 September 2009 Pages: 700 - 705
The notorious “drug lag” for oncology drugs in Japan Kan YonemoriAkihiro HirakawaYasuhiro Fujiwara PHASE III STUDIES 01 February 2011 Pages: 706 - 712
Proposal for size justification of expanded cohort at phase-2-recommended dose Nicolas PenelCharles FournierJocelyne Bérille SHORT REPORT 02 February 2010 Pages: 713 - 715
Avascular necrosis of the femoral head: a rare class-effect of anti-VEGF agents Olivier MirRomain CoriatFrançois Goldwasser SHORT REPORT 24 February 2010 Pages: 716 - 718